- Home
- VFL vs LFCR Comparison
VFL vs LFCR Comparison
Compare VFL & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VFL | LFCR |
|---|---|---|
| Founded | N/A | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.0M | 143.9M |
| IPO Year | 1994 | 1996 |
Fundamental Metrics
Financial Performance| Metric | VFL | LFCR |
|---|---|---|
| Price | $10.15 | $5.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 28.0K | ★ 190.4K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $557,559,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 6.36 |
| 52 Week Low | $9.38 | $3.63 |
| 52 Week High | $10.50 | $8.98 |
Technical Indicators
Market Signals| Indicator | VFL | LFCR |
|---|---|---|
| Relative Strength Index (RSI) | 51.04 | 64.06 |
| Support Level | $10.11 | $4.75 |
| Resistance Level | $10.33 | $8.55 |
| Average True Range (ATR) | 0.07 | 0.31 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 67.19 | 85.17 |
Price Performance
Historical ComparisonAbout VFL abrdn National Municipal Income Fund
Delaware Investments Natl Muni Income is a closed-end investment fund. The Fund's investment objective is to seek to provide current income exempt from regular federal income tax, consistent with the preservation of capital. The company's product portfolio includes Mutual funds, Exchange-traded funds, Private markets, and Closed-end funds.
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.